Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1010

Sort by

Sort Order Select

Journal Articles

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

Hermann Einsele, Per Ljungman, Michael Boeckh

Blood (2020) 135 (19): 1619–1629.

https://doi.org/10.1182/blood.2019000956

Published: 2020

Journal Articles

AL patients don’t dare go without dara

Angela Dispenzieri

Blood (2020) 135 (18): 1509–1510.

https://doi.org/10.1182/blood.2020005436

Published: 2020

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

Giuseppe Lia, PhD, Clara Di Vito, PhD, Marta Tapparo, PhD, Stefania Bruno, Elisa Zaghi, Michela Calvi, Lucia Brunello, Jacopo Mariotti, MD, Lorenzo Comba, Luisa Giaccone, Martina Fascì, Mario Boccadoro, Andrea Evangelista, MSc, Luca Castagna, MD, Giovanni Camussi, Domenico Mavilio, Benedetto Bruno, MD

Blood (2019) 134 (Supplement_1): 598.

https://doi.org/10.1182/blood-2019-126521

Published: 2019

Journal Articles

Comparative Analysis of Alpha-Beta T-Cell and B-Cell Depleted (abTCD) HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT) Versus Abtcd Haplo-HSCT with T-Cell Add-Back of Rivogenlecleucel Cell [Donor T Cells Transduced with the Inducible Caspase 9 (iC9) Gene Safety Switch] in Children with High-Risk Acute Leukemia (AL) in Remission

Annalisa Ruggeri, MD, Pietro Merli, MD, Mattia Algeri, MD, Marco Zecca, Franca Fagioli, MD, Giuseppina Li Pira, PhD, Valentina Bertaina, PhD, Arcangelo Prete, MD, Mauro Montanari, MD, Francesca Del Bufalo, MD, Luciana Vinti, MD, Daria Pagliara, MD PhD, Melissa Aldinger, PharmD, Kai Chan, Paul Woodard, Federica Galaverna, MD, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 145.

https://doi.org/10.1182/blood-2019-125366

Published: 2019

Journal Articles

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

William Pearse, MD, Barbara Pro, MD, Leo I. Gordon, MD, Reem Karmali, MD, Jane N. Winter, MD, Shuo Ma, MD PhD, Amir Behdad, MD, Andreas Klein, MD, Adam M. Petrich, MD, Borko Jovanovic, PhD, Sonali M. Smith, MD, Andrew G Evans, MD PhD

Blood (2019) 134 (Supplement_1): 351.

https://doi.org/10.1182/blood-2019-127390

Published: 2019

Journal Articles

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Amy E. DeZern, MD, Marianna Zahurak, MS, Kenneth R. Cooke, MD, David Margolis, MD, Richard J. Jones, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 147.

https://doi.org/10.1182/blood-2019-121900

Published: 2019

Journal Articles

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Patrice Chevallier, MD, Pierre Peterlin, Alice Garnier, MD, Amandine Le Bourgeois, MD, Beatrice Mahe, MD, Viviane Dubruille, MD, Nicolas Blin, MD, Cyrille Touzeau, MD, Thomas Gastinne, MD, Anne Lok, MD, Benoit Tessoulin, MD PhD, Yannick Le Bris, PharmD, Marie C Bene, PharmSci, PhD, Steven Le Gouill, MD PhD, Philippe Moreau, MD, Thierry Guillaume, MD PhD

Blood (2019) 134 (Supplement_1): 4528.

https://doi.org/10.1182/blood-2019-125787

Published: 2019

Journal Articles

Combination Therapy of Allogeneic HSCT and In Vivo Activated iNKT Cells Prevents Acute Gvhd While Augmenting GVL Effect

Samuel Zeng, Qingxiao Song, MD PhD, Shanshan Tang, Xi Wang, PhD, Yuchen Wang, PhD, Defu Zeng, MD PhD, Lili Yang, PhD

Blood (2019) 134 (Supplement_1): 4439.

https://doi.org/10.1182/blood-2019-130826

Published: 2019

Journal Articles

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Maria Queralt Salas, MD, Shiyi Chen, Wilson Lam, MD, David Loach, MD, Fotios V. Michelis, MD PhD, Zeyad Al-Shaibani, Dennis Dong Hwan Kim, MD PhD, Jeffrey H. Lipton, MD PhD, Auro Viswabandya, MDDM, Rajat Kumar, MD, Jonas Mattsson, MD, Arjun Law, MDDM

Blood (2019) 134 (Supplement_1): 4590.

https://doi.org/10.1182/blood-2019-126236

Published: 2019

Journal Articles

Pentotstatin/TBI Conditioning Is Well-Tolerated and Permits Engraftment of a Second Allogeneic Stem Cell Transplant Following Primary or Secondary Rejection of an Allogeneic Hematopoietic Stem Graft

Ani Gvajaia, MD, Amelia Langston, MD, Natia Esiashvil, MD, Michael Graiser, PhD, Kelly Valla, PharmD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5657.

https://doi.org/10.1182/blood-2019-122467

Published: 2019

Journal Articles

Rituximab for Desensitization during HLA-Mismatched Stem Cell Transplantation in Patients with a Positive Donor Specific Anti-HLA Antibody: A Prospective Study

Ying-Jun Chang, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei Han, Yu-Qian Sun, Chenhua Yan, Fei-Fei Tang, Ming-Rui Huo, Xiao-Dong Mo, MD, Xiang-Yu Zhao, Kai-yan Liu, Xiao-Jun Huang

Blood (2019) 134 (Supplement_1): 5622.

https://doi.org/10.1182/blood-2019-129781

Published: 2019

Journal Articles

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Lorenz Selberg, Peter Stadtherr, Sascha Dietrich, MD, Thomas Luft, MD PhD, Andrea Bondong, Ute Hegenbart, MD, Julia Meissner, MD, Nora Liebers, Michael Schmitt, MD, Carsten Mueller-Tidow, MD, Peter Dreger

Blood (2019) 134 (Supplement_1): 3328.

https://doi.org/10.1182/blood-2019-128352

Published: 2019

Journal Articles

Hematopoietic Mononuclear Cell Transplant with Minimal Gvhd in up to Completely Mismatched Unrelated Recipients

Suzanne T Ildstad, MD

Blood (2019) 134 (Supplement_1): 3243.

https://doi.org/10.1182/blood-2019-130943

Published: 2019

Journal Articles

Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen

Patrizia Chiusolo, Sabrina Giammarco, MD PhD, Teresa Lamparelli, Lucia Casarino, Monica Rossi, Alida Dominietto, MD, Anna Maria Raiola, MD, Francesca Gualandi, Carmen Di Grazia, MD, Silvia Betti, MD PhD, Federica Sorà, MD, Elena Rossi, MD PhD, Luciana Teofili, MD, Simona Sica, MD, Andrea Bacigalupo, MD, Emanuele Angelucci, MD

Blood (2019) 134 (Supplement_1): 4490.

https://doi.org/10.1182/blood-2019-126711

Published: 2019

Journal Articles

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Zachary D. Epstein-Peterson, MD, Paola Ghione, MD, Alison J. Moskowitz, MD, Parastoo B. Dahi, MD, Ahmet Dogan, MD PhD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, Miguel-Angel Perales, MD, Doris M Ponce, MD, David J. Straus, MD, Andrew D. Zelenetz, MD PhD, Craig S. Sauter, MD, Steven M. Horwitz, MD

Blood (2019) 134 (Supplement_1): 2850.

https://doi.org/10.1182/blood-2019-125376

Published: 2019

Journal Articles

Poor-Risk AML with Complex, Monosomal Karyotype: In Vivo Therapeutic Efficacy of Decitabine (DAC) in Patient-Derived Xenograft (PDX) Mouse Models

Gabriele Greve, PhD, Julia Schüler, DVM, Eva Oswald, PhD, Michael Lübbert

Blood (2019) 134 (Supplement_1): 2644.

https://doi.org/10.1182/blood-2019-126514

Published: 2019

Journal Articles

Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia

Ghayas C. Issa, MD, Christopher B. Benton, MD, Vakul Mohanty, PhD, Yifei Shen, PhD, Zoe Alaniz, Feng Wang, PhD, P. Andrew Futreal, PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Nicholas Navin, PhD, Marina Y Konopleva, MD PhD, Ken Chen, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 2717.

https://doi.org/10.1182/blood-2019-130540

Published: 2019

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Blood (2019) 134 (Supplement_1): 2926.

https://doi.org/10.1182/blood-2019-125740

Published: 2019

Journal Articles

Dynamic Easix Scores Closely Predict Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation

Mariam T. Nawas, MD, Miriam Sanchez-Escamilla, MD, Sean M. Devlin, PhD, Molly A. Maloy, MS, Sergio A Giralt, MD, Miguel-Angel Perales, MD, Michael Scordo, MD

Blood (2019) 134 (Supplement_1): 1971.

https://doi.org/10.1182/blood-2019-125834

Published: 2019

NARROW

How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation

AL patients don’t dare go without dara

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Plasmatic Extracellular Vesicles in Acute Graft-Versus-Host Disease after Haplo-Identical Allografting with Post-Transplant Cyclophosphamide

A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Ptcy + ATG Compared to Ptcy Alone As Gvhd Prophylaxis for Peripheral Blood Stem Cells Allotransplant Is Associated with Significant Lower Incidence of Acute Gvhd without Increasing Relapse or Death By Infection

Combination Therapy of Allogeneic HSCT and In Vivo Activated iNKT Cells Prevents Acute Gvhd While Augmenting GVL Effect

Reduced Intensity Conditioning and Dual T-Cell Modulation Improves Gvhd Free, Relapse Free Survival in AML Patients Compared with Myeloablative Conditioning

Pentotstatin/TBI Conditioning Is Well-Tolerated and Permits Engraftment of a Second Allogeneic Stem Cell Transplant Following Primary or Secondary Rejection of an Allogeneic Hematopoietic Stem Graft

Rituximab for Desensitization during HLA-Mismatched Stem Cell Transplantation in Patients with a Positive Donor Specific Anti-HLA Antibody: A Prospective Study

The Impact of Allogeneic Hematopoietic Cell Transplantation (alloHCT) on the Outcome of Poor-Risk Non-Hodgkin Lymphoma (NHL): A Retrospective Intent-to-Transplant (ITT) Analysis

Hematopoietic Mononuclear Cell Transplant with Minimal Gvhd in up to Completely Mismatched Unrelated Recipients

Full Donor Chimerism after Allografts for Myelofibrosis: The Role of Conditioning Regimen

Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience

Poor-Risk AML with Complex, Monosomal Karyotype: In Vivo Therapeutic Efficacy of Decitabine (DAC) in Patient-Derived Xenograft (PDX) Mouse Models

Identification of Gene Expression Signatures in Leukemia Stem Cells and Minimal Residual Disease Following Treatment of Adverse Risk Acute Myeloid Leukemia

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

Dynamic Easix Scores Closely Predict Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only